关于我们

Company Introduction

Shanghai United Cell Biotechnology Co., Ltd. ("SUCB" or "the Company"), originally founded by the UNILAB Group in 1995, is a subsidiary of Hillhouse Capital. Located at the Biotechnology Park in the Shanghai Pilot Free Trade Zone, SUCB is an integrated industrial base of research & development ("R&D"), manufacturing, and sales of genetically engineered biological products including vaccines – with a registered capital of USD 41.2 million. The Company's manufacturing facility covers a land area of 20,000 m2, with a building area of 24,000 m2, in which an annual production capacity of 12.8 million freeze-dried powder injections, 13 million liquid cartridges, 10 million capsule preparations, and 4 million bags of granular preparations are able to be made.

With the growth of its sales in the market, business expansion, and increase in production line, SUCB participated and capital input Zhuhai United Cell Biotechnology Co., Ltd. ("ZUCB" or "the Expansion Company") in 2015 in the Zhuhai High-tech Industrial Development Zone. With a registered capital of RMB 150 million, the Expansion Company's manufacturing facility is located at the Science and Technology Innovation Coast of the Zhuhai High-tech Zone. Shanghai United Cell Biotechnology Co., Ltd. will leverage its strong multinational network which the Company has built for over 20 years, in order to accomplish the goal of bringing China's biotechnology products to an international scale and providing opportunities and resources for China's biotechnology industry to achieve globalization.

Company History

  • 2018

    Launched of Ostiogen ®

  • 2014

    Launched of Pediatric format for OraVacs®

  • 2013

    GMP Certification of the New Plant (2010 version)

  • 2005

    Received IND approval for rhPTH (recombinant parathyroid hormone)

  • 2004

    Product Launch of OraVacs ®

  • 2002

    Product Launch Genheal ®

  • 2000

    Completion of the Shanghai Factory

  • 查看更多

Quality and Production

Quality Management and Production

SUCB has 5000 square meters production facility that has been approved by China’s GMP (Good Manufacturing Practice) 2010 version which includes workshops for gene process liquid raw material, vibrio cholera, lyophilized powder for injection, capsule preparation and solid preparation. Major equipments are state-of-the-art biotechnology instruments purchased domestically and imported from Europe to make sure that product quality is stable and reliable.

GMP Certifications and Quality Certificates

SUCB continuously adheres to a great importance of quality management that creates a healthy life and contributes to mankind. SUCB’s quality management system covers pharmaceutical production, inspection and distribution, continuously linking towards international standard. The independent quality assurance department closely monitors the implementation of the quality management system and strictly controls the entire process from material entering the facility to product release.

The National Drug Administration does random inspection checks and batch release inspection for vaccine products, SUCB’s random inspection quality performance rate and OraVacs®’ batch release inspection quality rate have reached 100%. Company’s production, quality and other technical personnel are all well trained professionals and regularly receives comprehensive professional and management training knowledge and skills to maintain technological improvement and management.

Honors and Awards

  • 2014 Shanghai Pharmaceutical Industry Branded Product
  • People’s Choice for Best Enterprise
  • Philanthropist Award